Hit enter to search or ESC to close
Immuneering Corporation
  • ABOUT
    • Our Approach
    • Team
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
  • ABOUT
    • Our Approach
    • Team
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
All Posts By

immun-ops2020

immun-ops2020 In Publications

Cachexia mechanisms in cancer through the lens of transcriptomics

Introduction: Cachexia is a major clinical complication that affects up to 80% of patients with advanced cancer, and by some estimates is responsible for 20% of cancer deaths [1]. Despite…

Read More
immun-ops2020 In Publications

The international MAQC Society launches to enhance reproducibility of high-throughput technologies

Reproducibility is a fundamental hallmark of good science. The US Food and Drug Administration (FDA)-led Microarray and Sequencing Quality Control (MAQC/SEQC) consortia conducted three projects 1,2,3 to assess the reliability and…

Read More
immun-ops2020 In Publications

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice

Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the…

Read More
immun-ops2020 In News

Proteomic Profiling Reveals Targetable Pathways in MGUS (SLAMF6, TNFRSF8, TIMP1, TRL2) That May Contribute to Disease Progression

Monoclonal gammopathy of undetermined significance (MGUS), is a pre-malignant plasma cell disorder that affects roughly 4% of the population older than 55 and is associated with a 1% per year…

Read More
immun-ops2020 In Publications

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice

Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the…

Read More
immun-ops2020 In Publications

Proteomic Profiling Reveals Targetable Pathways in MGUS (SLAMF6, TNFRSF8, TIMP1, TRL2) That May Contribute to Disease Progression Blood 2017 130:3805;

Monoclonal gammopathy of undetermined significance (MGUS), is a pre-malignant plasma cell disorder that affects roughly 4% of the population older than 55 and is associated with a 1% per year…

Read More
immun-ops2020 In Publications

Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.

Copaxone (glatiramer acetate, GA), a structurally and compositionally complex polypeptide nonbiological drug, is an effective treatment for multiple sclerosis, with a well-established favorable safety profile. The short antigenic polypeptide sequences…

Read More
immun-ops2020 In News

Transcriptomic analysis of the YAC128 HD mouse model shows disease mechanisms are ameliorated by pridopidine.

Huntington Disease (HD) is a neurodegenerative disorder hallmarked by the expression of a mutant form of the huntingtin gene (mHtt). A therapeutic goal for HD treatment involves the restoration of…

Read More
immun-ops2020 In Publications

Transcriptomic analysis of the YAC128 HD mouse model shows disease mechanisms are ameliorated by pridopidine.

Huntington Disease (HD) is a neurodegenerative disorder hallmarked by the expression of a mutant form of the huntingtin gene (mHtt). A therapeutic goal for HD treatment involves the restoration of…

Read More
immun-ops2020 In News

A meta-metastasis analysis identifies pan-cancer markers and therapeutic targets

Introduction: Targeting metastasis has the potential to reduce the lethality of cancer, instead making it a manageable disease. While metastasis has been studied extensively in individual forms of cancer, less…

Read More
Previous 1 … 6 7 8 9 10 … 13 Next
Immuneering logo
  • ABOUT
  • PLATFORM
  • PIPELINE
  • PUBLICATIONS
  • FOR INVESTORS
  • CONTACT
  • Terms of Use
  • Privacy Policy

© 2025 Immuneering Corporation.